文献速递乳腺乳腺X线

基于人群的乳腺癌筛查中数字乳腺断层摄影的成本效果:一项概率敏感性分析

Cost-effectiveness of Digital Breast Tomosynthesis in Population-based Breast Cancer Screening: A Probabilistic Sensitivity Analysis.
PubMed 文献 · Radiology · 2020-08-04

该研究在荷兰基于人群的乳腺癌筛查背景下,采用微观模拟筛查分析模型进行概率敏感性分析,比较50至74岁女性每两年一次数字乳腺断层摄影(DBT)与数字乳腺摄影(DM)的终身效果与成本。DBT每1000名受邀女性增加13个生命年、减少2%假阳性,增量成本效果比为每获得1个生命年27023欧元;在每生命年20000欧元意愿支付阈值下DBT更具成本效果的概率为0.36,在35000欧元阈值下为0.66。

要点

  • DBT每1000名受邀女性增加13个生命年(7%增幅,193个中的13个),并减少2%假阳性(159个中的4个)。
  • DBT增量成本效果比为每获得1个生命年27023欧元(29725美元)。
  • DBT更具成本效果的概率在每生命年20000欧元阈值下为0.36,在35000欧元阈值下为0.66。

核心结论

  • 在每生命年20000欧元意愿支付阈值下,从数字乳腺摄影转为每两年一次数字乳腺断层摄影不具有成本效果。
  • 在每生命年35000欧元意愿支付阈值下,数字乳腺断层摄影比数字乳腺摄影更具成本效果的概率更高。

研究设计与样本

  • 研究于2018年3月至2019年2月进行,使用微观模拟筛查分析模型开展概率敏感性分析,包含10000次模型运行,每次运行模拟1000000名女性。
  • 模拟两个出生于1970年的队列,均在50至74岁之间每两年受邀筛查一次,一个队列分配至数字乳腺摄影筛查,另一个分配至数字乳腺断层摄影筛查。
  • 数字乳腺摄影输入参数基于荷兰乳腺癌筛查项目数据,数字乳腺断层摄影参数基于文献和专家意见。
  • 采用贝叶斯成本效果分析包和谢菲尔德加速信息价值工具处理概率敏感性分析结果,效果和成本按每年3.5%贴现。

诊断标准与关键数值

  • 意愿支付阈值考虑每获得1个生命年20000欧元(22000美元)和35000欧元(38500美元)。
  • 与数字乳腺摄影相比,数字乳腺断层摄影每1000名受邀女性增加13个生命年(7%增幅,193个中的13个),并减少2%假阳性(159个中的4个)。
  • 数字乳腺断层摄影的增量贴现终身效果为5.09个生命年(95%置信区间:-0.80,9.70),每1000名女性终身成本增加137555欧元(151311美元)(95%置信区间:31093欧元[34202美元],263537欧元[289891美元])。
  • 平均增量成本效果比为每获得1个生命年27023欧元(29725美元)。
  • 数字乳腺断层摄影更具成本效果的概率在每生命年20000欧元阈值下为0.36,在每生命年35000欧元阈值下为0.66。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BackgroundDigital breast tomosynthesis (DBT) is a promising screening test, but its outcomes and cost-effectiveness remain uncertain.PurposeTo determine if biennial DBT is cost-effective in a screening setting, when compared with digital mammography (DM) in the Netherlands, and to quantify the uncertainty.Materials and MethodsIn this study, performed from March 2018 to February 2019, the MIcrosimulation SCreening ANalysis model was used to conduct a probabilistic sensitivity analysis (PSA), consisting of 10 000 model runs with 1 000 000 women simulated per run. The Bayesian Cost-Effectiveness Analysis package and the Sheffield Accelerated Value of Information tool were used to process PSA outcomes. Two simulated cohorts born in 1970 were invited to undergo biennial screening between ages 50 and 74 years-one cohort was assigned to DM screening, and one was assigned to DBT screening. DM input parameters were based on data from the Dutch breast cancer screening program. DBT parameters were based on literature and expert opinion. Willingness-to-pay thresholds of €20 000 ($22 000) and €35 000 ($38 500) per life-year gained (LYG) were considered. Effects and costs were discounted at 3.5% per year.ResultsDBT resulted in a gain of 13 additional life-years per 1000 women invited to screening (7% increase, 13 of 193), followed over lifetime, compared with DM and led to 2% (four of 159) fewer false-positive results. DBT screening led to incremental discounted lifetime effects of 5.09 LYGs (95% confidence interval: -0.80, 9.70) and an increase in lifetime costs of €137 555 ($151 311) per 1000 women (95% confidence interval: €31 093 [$34 202], €263 537 [$289 891]) compared with DM, resulting in a mean incremental cost-effectiveness ratio of €27 023 ($29 725) per LYG. The probability of DBT being more cost-effective was 0.36 at €20 000 and 0.66 at €35 000 per LYG.ConclusionSwitching from digital mammography to biennial digital breast tomosynthesis is not cost-effective at a willingness-to-pay threshold of €20 000 per life-year gained, but digital breast tomosynthesis has a higher probability of being more cost-effective than digital mammography at a threshold of €35 000 per life-year gained.© RSNA, 2020Online supplemental material is available for this article.See also the editorial by Slanetz in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Sankatsing VDV, Juraniec K, Grimm SE, et al. Cost-effectiveness of Digital Breast Tomosynthesis in Population-based Breast Cancer Screening: A Probabilistic Sensitivity Analysis. Radiology. 2020. PMID: 32749212. doi:10.1148/radiol.2020192505

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。